Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy adolescent/adult subjects between and including 16 and 25 years of age at the time of screening.~  * Written informed consent obtained from the subject prior to enrolment.~ * Seronegative for EBV antibody.~Exclusion Criteria:~* Administration of immunoglobulin and/or any blood products within the three months (90 days) preceding the first dose of study vaccine or planned administration during the study period.~  * Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.~ * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.~ * Family history of congenital or hereditary immunodeficiency.~ * Major congenital defects or serious chronic illness.~ * History of any neurologic disorders or seizures, with the exception of a single febrile seizure during childhood.~ * Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.~ * History of intravenous drug abuse within the past 2 years.~ * Known or suspected allergy to any vaccine component.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).